SCHEMBL5743776

SCHEMBL5743776

O=C(O)C(Br)Cc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.54
PPARA Q07869 15/20 0.54
SLC6A4 P31645 1/20 0.47
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11071239 0.86 NR4A2 (0.61) PPARGPPARA
SCHEMBL27700293 0.86 SLC6A4 (0.48) PPARGPPARASLC6A4SLC6A2SLC6A3
SCHEMBL4283538 0.82 SLC6A2 (0.47) PPARGPPARASLC6A4SLC6A2SLC6A3
SCHEMBL4795941 0.82 SLC7A5 (0.60) SLC6A2
SCHEMBL27807869 0.82 MME (0.51) PPARGPPARA
SCHEMBL4826192 0.81 CYP1A2 (0.61)
SCHEMBL4316458 0.81 CYP1A2 (0.61)
SCHEMBL6712771 0.81 PPARG (0.59) PPARGPPARASLC6A4SLC6A2SLC6A3
SCHEMBL490844 0.81 CYP1A2 (0.61)
SCHEMBL20766143 0.80 CPA1 (0.51) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113929618-B Oxo-pyridine amide derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-08-11 CN disclosed
CN-113912586-B Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-04-07 CN disclosed
CN-113929618-A Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2022-01-14 CN disclosed
CN-113912586-A Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2022-01-11 CN disclosed
EP-3486242-B1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO (CN) 2021-12-08 EP disclosed
CN-108495850-B Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2021-11-26 CN disclosed
US-11084808-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-08-10 US disclosed
US-20200199115-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2020-06-25 US disclosed
US-10633375-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof Jinagsu Hengrui Medicine Co., Ltd (CN) 2020-04-28 US disclosed
US-20190185464-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2019-06-20 US disclosed
EP-3486242-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2019-05-22 EP disclosed
CN-101967129-B Preparation method of 4-aryl-1H-1, 2, 3-triazole UNIV TONGJI 2012-02-29 CN disclosed
CN-101967129-A Preparation method of 4-aryl-1H-1, 2, 3-triazole UNIV TONGJI 2011-02-09 CN disclosed
EP-1173427-B1 HYDROXAMIC ACID DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2006-04-05 EP disclosed
CN-1658871-A Amide derivatives as GK activators NOVO NORDISK AS (DK) 2005-08-24 CN disclosed
US-6713477-B1 1,4-BENZTHIAZINES OR BENZOXAZINES; MATRIX METALLOPROTEINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-30 US disclosed
EP-1173427-A1 HYDROXAMIC ACID DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-01-23 EP disclosed
WO-2000063197-A1 HYDROXAMIC ACID DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10633375-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof F11, F2, F7 PPARG 3318/4885PPARA 3176/4885SLC6A4 2756/4885
US-20200199115-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, F2, F7 PPARG 3622/4885PPARA 3333/4885SLC6A4 2836/4885
US-20190185464-A1 OXOPICOLINAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, F2, F7 PPARG 3318/4885PPARA 3176/4885SLC6A4 2756/4885
US-11084808-B2 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof F11, F2, F7 PPARG 3318/4885PPARA 3176/4885SLC6A4 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.